EGFR and neoplasm: The described biomarkers identified the investigated tumor-positive and -negative lymph nodes correctly with, respectively, a sensitivity and specificity of; αvβ6 (84%; 100%), CEACAM5 (68%; 100%), EGFR (93%; 67%), Cath E (54%; 83%), and uPAR (69%; 67%).